Lightnews — Scholar-powered news

Reposted by Vivek Subbiah, MD

OncoDaily @oncodaily.bsky.social · 3d

Smarter Trial Designs: How Project Optimus is Changing Early-Phase Cancer Research - Vivek Subbiah

@viveksubbiah.bsky.social

oncodaily.com/voices/vivek...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews

Vivek Subbiah: Smarter Trial Designs - How Project Optimus is Changing Early-Phase Cancer Research - OncoDaily

Vivek Subbiah: Smarter Trial Designs - How Project Optimus is Changing Early-Phase Cancer Research / American Society of Clinical Oncology, ASCO, cancer,

oncodaily.com

1 4

Reposted by Vivek Subbiah, MD

Jia (Jenny) Liu MD PhD @jiajennyliu.bsky.social · 1d

D-7 until #ESMO25! 👋🇩🇪

Excited to be part of first ever tumor-agnostic scientific track with @viveksubbiah.bsky.social @JulianaRBeale #NiamhColeman

Don’t miss these educational sessions! ⬇️ @myesmo.bsky.social

2 3

Reposted by Vivek Subbiah, MD

OncoDaily @oncodaily.bsky.social · 11d

Impact of FDA Project Optimus Guidance on Early-Phase Trial Design - Vivek Subbiah

@viveksubbiah.bsky.social @fda.gov

oncodaily.com/voices/vivek...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews

Vivek Subbiah: Impact of FDA Project Optimus Guidance on Early-Phase Trial Design - OncoDaily

Vivek Subbiah: Impact of FDA Project Optimus Guidance on Early-Phase Trial Design / cancer, David Spigel, Deepak Bhamidipati, Gerald Falchook, Howard Burris,

oncodaily.com

1 3

Reposted by Vivek Subbiah, MD

OncoDaily @oncodaily.bsky.social · 17d

Honored to Join Global Colleagues and Deliver the Message at the UN for The Last Mile Series - Vivek Subbiah

@viveksubbiah.bsky.social

oncodaily.com/voices/vivek...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews

Vivek Subbiah: Honored to Join Global Colleagues and Deliver the Message at the UN for The Last Mile Series - OncoDaily

Vivek Subbiah: Honored to Join Global Colleagues and Deliver the Message at the UN for The Last Mile Series / cancer, International Cancer Patient Coalition,

oncodaily.com

2 5

Vivek Subbiah, MD @viveksubbiah.bsky.social · 12d

⭐️When AI rejects your grant proposal: algorithms are helping to make funding decisions
A foundation using an AI tool to screen grant applications says it makes the peer-review process more efficient, but other researchers say it’s a breakdown in trust
www.nature.com/articles/d41...

When AI rejects your grant proposal: algorithms are helping to make funding decisions

A Spanish foundation using an artificial-intelligence tool to screen grant applications says it makes the peer-review process more efficient, but other researchers say it’s a breakdown in trust.

www.nature.com

1 1 2

Reposted by Vivek Subbiah, MD

Gregory Riely @rielymd.bsky.social · 18d

Appropriately critical commentary on cochrane reviews as the apply to matched targeted therapy by @viveksubbiah.bsky.social Journal of Clinical Oncology ascopubs.org/doi/full/10....

Precision Oncology and Modernizing Evidence Standards: A Critical Commentary on the Cochrane Review

ascopubs.org

3 2

Reposted by Vivek Subbiah, MD

Syed Mohi Ahmed, MD, PhD @smohahm.bsky.social · Aug 12

PFS benefit noted with adagrasib

Vivek Subbiah, MD @viveksubbiah.bsky.social · Aug 11

Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial - The Lancet www.thelancet.com/journals/lan...

Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial

Adagrasib demonstrated a statistically significant improvement in progression-free survival over docetaxel in patients with previously treated KRASG12C-mutated NSCLC, without new safety signals.

www.thelancet.com

1 1 3

Reposted by Vivek Subbiah, MD

OncoDaily @oncodaily.bsky.social · Aug 24

10 Must-Read Posts in Immuno-Oncology This Week

@viveksubbiah.bsky.social @jiajennyliu.bsky.social @gerryhanna.bsky.social @drjnaidoo.bsky.social

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #IO #ImmuneOncology

10 Must-Read Posts in Immuno-Oncology This Week - OncoDaily

10 Must-Read Posts in Immuno-Oncology This Week / Alex Menzies, Alexander Van Akkooi, AndrewFurness, cancer, chemoimmunotherapy, Christian Blank, David

oncodaily.com

1 10

Reposted by Vivek Subbiah, MD

OncoDaily @oncodaily.bsky.social · Sep 4

Nature Medicine Study on Molecular Profiling in Meningioma - @viveksubbiah.bsky.social

oncodaily.com/science/vive...

#OncoDaily #Oncology #Cancer #Health #Medicine

Vivek Subbiah: Nature Medicine Study on Molecular Profiling in Meningioma - OncoDaily

Vivek Subbiah: Nature Medicine Study on Molecular Profiling in Meningioma / Alexander P. Landry, Andrew Ajisebutu, cancer, Chloe Gui, Farshad Nassiri, Gelareh

oncodaily.com

1 6

Reposted by Vivek Subbiah, MD

OncoDaily @oncodaily.bsky.social · 28d

Rare Cancers Deserve Breakthroughs Too - Vivek Subbiah

@viveksubbiah.bsky.social @conquercancer.bsky.social

oncodaily.com/blog/rare-ca...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews

Vivek Subbiah: Rare Cancers Deserve Breakthroughs Too - OncoDaily

Vivek Subbiah: Rare Cancers Deserve Breakthroughs Too / American Society of Clinical Oncology, ASCO, cancer, Conquer Cancer, Conquer Cancer the ASCO

oncodaily.com

1 4

Reposted by Vivek Subbiah, MD

OncoDaily @oncodaily.bsky.social · 27d

Top Articles Suggested by Vivek Subbiah

@viveksubbiah.bsky.social

oncodaily.com/voices/vivek...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews

Top Articles Suggested by Vivek Subbiah - OncoDaily

Top Articles Suggested by Vivek Subbiah / cancer, Nature, NEJM, OncoDaily, Oncology, Vivek Subbiah

oncodaily.com

1 3

Reposted by Vivek Subbiah, MD

JAMA Oncology @jamaoncology.com · 22d

🔊 Listen to Jiyoung Ahn, PhD, of New York University, discuss with @viveksubbiah.bsky.social, MD, about whether the oral bacterial and fungal microbiome is associated with the development of pancreatic #cancer.

Listen now: ja.ma/41Vzuh9

Oral Bacterial and Fungal Microbiome and Subsequent Risk for Pancreatic Cancer

Interview with Jiyoung Ahn, PhD, author of Oral Bacterial and Fungal Microbiome and Subsequent Risk for Pancreatic Cancer. Hosted by Vivek Subbiah, MD.

ja.ma

1 1

Reposted by Vivek Subbiah, MD

OncoDaily @oncodaily.bsky.social · 19d

Congratulations to Petros Grivas on Being Named Medical Director of Fred Hutch Cancer Center - Vivek Subbiah

@viveksubbiah.bsky.social @fredhutch.org

oncodaily.com/career/vivek...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews

Vivek Subbiah: Congratulations to Petros Grivas on Being Named Medical Director of Fred Hutch Cancer Center - OncoDaily

Vivek Subbiah: Congratulations to Petros Grivas on Being Named Medical Director of Fred Hutch Cancer Center / cancer, Fred Hutch Cancer Center, OncoDaily,

oncodaily.com

1 5

Reposted by Vivek Subbiah, MD

OncoDaily @oncodaily.bsky.social · 19d

Top 5 Articles of the Week Suggested by Vivek Subbiah

@viveksubbiah.bsky.social

oncodaily.com/voices/vivek...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews

Top 5 Articles of the Week Suggested by Vivek Subbiah - OncoDaily

Top 5 Articles of the Week Suggested by Vivek Subbiah / cancer, Cancer Discovery, Nature, OncoDaily, Oncology, Sarah Cannon Research Institute, Vivek Subbiah

oncodaily.com

2 5

Vivek Subbiah, MD @viveksubbiah.bsky.social · Aug 11

Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial - The Lancet www.thelancet.com/journals/lan...

Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial

Adagrasib demonstrated a statistically significant improvement in progression-free survival over docetaxel in patients with previously treated KRASG12C-mutated NSCLC, without new safety signals.

www.thelancet.com

1 2 5

Vivek Subbiah, MD @viveksubbiah.bsky.social · Aug 11

Patterns in genomic mutations among patients with early-onset colorectal cancer: an international, multicohort, observational study - The Lancet Oncology www.thelancet.com/journals/lan...

Patterns in genomic mutations among patients with early-onset colorectal cancer: an international, multicohort, observational study

Within hypermutated colorectal cancer, younger patients exhibited a higher mutational burden than older patients. Our study reveals an abnormal accumulation of distinct somatic mutations in hypermutat...

www.thelancet.com

3 5

Vivek Subbiah, MD @viveksubbiah.bsky.social · Aug 11

Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol - The Lancet Oncology www.thelancet.com/journals/lan...

Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol

We did not find significant evidence of an overall survival benefit of adding metformin to standard of care in the overall population of patients with metastatic hormone-sensitive prostate cancer. The...

www.thelancet.com

3

Reposted by Vivek Subbiah, MD

OncoDaily @oncodaily.bsky.social · Jul 21

What is Missing to Fully Harness Precision Medicine and Transform Cancer Care - Vivek Subbiah
@viveksubbiah.bsky.social
@natmed.nature.com

oncodaily.com/blog/vivek-s...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #PrecisionMedicine

Vivek Subbiah: We Don’t Just Write What We Know, We Write to Discover What We Could Know - OncoDaily

Vivek Subbiah: We Don’t Just Write What We Know, We Write to Discover What We Could Know / cancer, Nature Reviews Bioengineering, OncoDaily, Oncology, Vivek

oncodaily.com

2 5

Reposted by Vivek Subbiah, MD

OncoDaily @oncodaily.bsky.social · Jul 7

It’s Time We Evolve WHO Cancer Classification - Vivek Subbiah
@viveksubbiah.bsky.social
@who.int

oncodaily.com/science/vive...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #CancerClassification #WHO

Vivek Subbiah: It’s Time We Evolve WHO Cancer Classification - OncoDaily

Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn: “Happy 4th everyone! Delighted to share with the our comment just published in t...

oncodaily.com

2 8

Reposted by Vivek Subbiah, MD

OncoDaily @oncodaily.bsky.social · Jul 5

How Clinical Trials Offer Hope for Those Facing Limited Options - Vivek Subbiah
@viveksubbiah.bsky.social

oncodaily.com/blog/clinica...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ClinicalTrial #Sarcoma #SarcomaAwarenessMonth

Vivek Subbiah: How Clinical Trials Offer Hope for Those Facing Limited Options - OncoDaily

Vivek Subbiah: How Clinical Trials Offer Hope for Those Facing Limited Options / cancer, OncoDaily, Oncology, Sarah Cannon Research Institute, Sarcoma

oncodaily.com

1 5

Reposted by Vivek Subbiah, MD

Vivek Subbiah, MD @viveksubbiah.bsky.social · May 29

⭐️Tissue-agnostic cancer therapies: promise, reality, and the path forward
@natcomms.nature.com @ascocancer.bsky.social #ASCO25
www.nature.com/articles/s41...

Tissue-agnostic cancer therapies: promise, reality, and the path forward - Nature Communications

Tissue-agnostic cancer therapies promise to revolutionize oncology by targeting molecular drivers. Sledge et al.’s study of nearly 300,000 tumors found 21.5% with tissue-agnostic indications. Despite ...

www.nature.com

3 15

Reposted by Vivek Subbiah, MD

Vivek Subbiah, MD @viveksubbiah.bsky.social · Apr 8

🚨 Hot off the press! 🚨 The @myesmo.bsky.social ESMO Precision Oncology Working Group, has unveiled key "Recommendations for structuring Molecular Tumour Boards (MTBs) in clinical practice", now published in ESMO's flagship journal Annals of Oncology 🧬🏥
www.annalsofoncology.org/article/S092...

1 3 10

Reposted by Vivek Subbiah, MD

OncoDaily @oncodaily.bsky.social · Jun 22

Cancer Isn’t Just a Human Disease – It’s a Biological Reality Across Species, From Dogs to Tigers to the Extinct Dinosaurs - Vivek Subbiah
@viveksubbiah.bsky.social

oncodaily.com/blog/vivek-s...

#OncoDaily #Oncology #Cancer #Medicine #Health

Vivek Subbiah: Cancer Isn’t Just a Human Disease - It’s a Biological Reality Across Species, From Dogs to Tigers to the Extinct Dinosaurs - OncoDaily

Vivek Subbiah: Cancer Isn’t Just a Human Disease - It’s a Biological Reality Across Species, From Dogs to Tigers to the Extinct Dinosaurs / Amy M. Boddy,

oncodaily.com

1 5

Reposted by Vivek Subbiah, MD

OncoDaily @oncodaily.bsky.social · Jun 17

25 Posts Not to Miss from EHA 2025
@nicogagelmann.bsky.social @talhabadarmd.bsky.social @majorajay.bsky.social @vincentrk.bsky.social @viveksubbiah.bsky.social @nejm.org

oncodaily.com/societies/eh...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #EHA2025 #EHA25

25 Posts Not to Miss from EHA 2025: - OncoDaily

The European Hematology Association (EHA 2025) congress is officially underway in Milan. From June 12 to 15, hematology professionals from

oncodaily.com

3 9

Reposted by Vivek Subbiah, MD

OncoDaily @oncodaily.bsky.social · Jun 15

Why Every Rare Cancer Patient Deserves Molecular Profiling? - Vivek Subbiah
@viveksubbiah.bsky.social

oncodaily.com/insight/vive...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #RareCancers #MolecularProfiling

Vivek Subbiah: Why Every Rare Cancer Patient Deserves Molecular Profiling? - OncoDaily

Vivek Subbiah: Why Every Rare Cancer Patient Deserves Molecular Profiling? / Bettina Ryll, Branko Cuglievan, cancer, clinical trials, FDA, Howard A. Burris

oncodaily.com

4 15